Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867815 · ClinicalTrials.gov registry record · Phase 4
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00867815 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 10 participants.
The verdict
NCT00867815, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
Interventions
- DRUG Diagnostic procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-07-13 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867815
The ClinicalTrials.gov registry entry for NCT00867815 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic procedures is the first listed.
NCT00867815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867815 about?
NCT00867815 is a clinical study titled "PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)". The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
What is the current status of trial NCT00867815?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2009-07-13. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT00867815?
The interventions under investigation include: Diagnostic procedures (DRUG).
Who is sponsoring clinical trial NCT00867815?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.